Comprehensive Prehabilitation Program for Locally Advanced Esophagogastric Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Patients with locally advanced esophageal, GEJ, or gastric cancer undergoing perioperative therapy and surgery will receive an integrated prehabilitation program including tailored nutrition, an at-home exercise plan, ERAS-inspired perioperative care, and ongoing psychological support. The study aims to see whether these measures improve fitness, recovery, and postoperative outcomes compared with standard care. HRV and aerobic capacity will be monitored to gauge autonomic and cardiorespiratory changes during the preoperative period. The approach targets optimizing physical condition and well-being to reduce perioperative morbidity in a context where treatment can be harsh. The program is designed to be feasible for patients who can participate in exercise and follow a nutritional plan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Consent to participate in the study
* Age ≥ 18 years
* Patients with locally advanced esophageal or gastric cancer indicated for comprehensive perioperative treatment
* Resectable disease
* ECOG performance status 0-2
* Ability to participate in a fitness program
* Willingness to follow a nutritional plan and recommendations

Exclusion Criteria:

* Disseminated disease

Where it's running

• Masaryk Memorial Cancer Institute
  Brno, Czechia Recruiting

Study contacts

• Principal investigator: Radka Lordick Obermannová, Doc, MD, PhD — Masaryk Memorial Cancer Institute
• Study coordinator: Martina Lojová, PhD
• Email: martina.lojova@mou.cz
• Phone: +420543136232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Observational look at how adults with stomach and GEJ cancer are diagnosed and treated in Greece

  This study will look at real-world care for adults with stage II-IVB gastric or gastroesophageal junction cancer in Greece to see how they are diagnosed and managed in usual practice.

  Recruiting at 3 sites AstraZeneca · Alexandroupoli and 8 other locations · NCT07800754

• Cadonilimab with chemotherapy for gastric or GEJ cancer

  This trial tests whether adding cadonilimab to standard chemotherapy is safe and effective for adults with locally advanced or resectable gastric or GEJ cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07631000

• Adebrelimab with SHR-A1811/SHR-A1904 plus chemotherapy or with SHR-8068 for gastric and gastroesophageal-junction cancer

  This trial tests whether adding Adebrelimab to SHR-A1811 or SHR-A1904 plus chemotherapy, or combining Adebrelimab with SHR-8068, improves outcomes for adults newly diagnosed with gastric or gastroesophageal-junction cancer who have not yet received treatment.

  Recruiting at 2 sites Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shijiazhuang, Hebei and 1 other locations · NCT07110571

• DR-0202 for advanced, relapsed, or treatment-resistant carcinomas

  This trial tests DR-0202 in adults with advanced or metastatic carcinomas—such as certain breast, lung, cervical, and prostate cancers—that have relapsed or stopped responding to standard treatments.

  Recruiting at 10 sites Phase 1 Dren Bio · Denver, Colorado and 9 other locations · NCT06999187

• Combination treatment for advanced HER2-positive gastric cancer

  This study is testing a new combination treatment for adults with advanced HER2-positive gastric cancer to see if it works better than the standard treatment.

  Recruiting at 219 sites Phase 3 Daiichi Sankyo · New Haven, Connecticut and 249 other locations · NCT06731478

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.